|Place of Origin:||China|
|Model Number:||Lyophilized, 40mg|
|Minimum Order Quantity:||100, 000 vials|
|Payment Terms:||L/C, T/T|
|Supply Ability:||300, 000 vials per day|
|Product:||Pantoprazole Sodium For Injection||Specification:||Lyophilized, 40mg|
Lyophilized Powder Injection / Pantoprazole Sodium For Injection 40mg Anti acid Anti Reflux
Product : Pantoprazole Sodium For Injection
Specification : Lyophilized, 40mg
Standard : BP, USP
Packing : 50vials/box
Therapeutic class: Proton Pump Inhibitor (PPI)
Route of administration: For Intravenous use only
Pantoprazole Sodium for Injection is supplied as a freeze-dried powder in a clear glass vial fitted with a rubber stopper and crimp seal containing pantoprazole sodium, equivalent to 40 mg of pantoprazole, edetate disodium (1 mg), and sodium hydroxide to adjust pH.
Indications and Usage
1.1 Gastroesophageal Reflux Disease Associated With a History of Erosive Esophagitis
Pantoprazole Sodium for Injection is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis.
Safety and efficacy of Pantoprazole Sodium for Injection as a treatment of patients with GERD and a history of erosive esophagitis for more than 10 days have not been demonstrated.
1.2 Pathological Hypersecretion Including Zollinger-Ellison Syndrome
Pantoprazole Sodium for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome in adults.
Pantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production.
Mechanism of Action :
Interferes with gastric acid secretion by inhibiting the hydrogen-potassium-adenosine triphosphatase (H+-K+-ATPase) enzyme system, or proton pump, in gastric parietal cells. Normally, the proton pump uses energy from hydrolysis of ATPase to drive H+ and chloride (Cl−) out of parietal cells and into the stomach lumen in exchange for potassium (K+), which leaves the stomach lumen and enters parietal cells. After this exchange, H+ and Cl− combine in the stomach to form hydrochloric acid (HCl). Pantoprazole irreversibly inhibits the final step in gastric acid production by blocking the exchange of intracellular H+ and extracellular K+, thus preventing H+ from entering the stomach and additional HCl from forming.